1. Show article details.

    Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing

    PR Newswire – 8:00 AM ET 07/07/2020

    CAMBRIDGE, Mass. Tessera's Gene Writing platform is a potentially revolutionary breakthrough for genetic medicine that addresses key limitations of gene therapy and gene editing.

  2. Show article details.

    BRIEF-Axcella Announces Patent Issuances Covering AXA1665

    Reuters – 8:02 AM ET 06/17/2020

    Axcella Health Inc (AXLA): * AXCELLA ANNOUNCES PATENT ISSUANCES COVERING AXA1665 Source text for Eikon: Further company coverage:

  3. Show article details.

    Axcella Announces Patent Issuances Covering AXA1665

    Business Wire – 8:00 AM ET 06/17/2020

    Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, today announced the issuance of two new patents: U.S. Patent 10,682,325 and U.S. Patent 10,660,870. U.S. Patent 10,682,325 covers the composition of AXA1665 as well as other related EMM compositions.

  4. Show article details.

    BRIEF-Axcella Health Says Entered Into Sales Agreement With SVB Leerink Relating To Shares Of Common Stock Offered By Prospectus

    Reuters – 5:45 PM ET 06/12/2020

    Axcella Health Inc (AXLA): * AXCELLA HEALTH (AXLA) - ENTERED INTO SALES AGREEMENT WITH SVB LEERINK LLC RELATING TO SHARES OF COMMON STOCK OFFERED BY PROSPECTUS. * AXCELLA HEALTH (AXLA) - MAY OFFER, SELL SHARES OF COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $35 MILLION FROM TIME TO TIME Source: https://bit.ly/37p459j Further company coverage:

  5. Show article details.

    BRIEF-Axcella Health Files For $125 Million Mixed Shelf

    Reuters – 5:25 PM ET 06/05/2020

    Axcella Health Inc (AXLA): * AXCELLA HEALTH FILES FOR $125 MILLION MIXED SHELF - SEC FILING Source text: Further company coverage:

  6. Show article details.

    Axcella to Present at Goldman Sachs 41st Annual Global Healthcare Conference

    Business Wire – 8:00 AM ET 06/03/2020

    Presentation and webcast to take place at 3:50 p.m. ET on June 10 Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, today announced that management will be presenting at the Goldman Sachs 41st Annual Global Healthcare Conference, which is being held virtually, on Jun...

  7. Show article details.

    Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity

    PR Newswire – 8:00 AM ET 05/28/2020

    CAMBRIDGE, Mass. "The newly created role of CEO-Partner ensures that our CEOs are an integral part of the Flagship leadership team and enables them to work more seamlessly as part of Flagship," says Noubar Afeyan, Ph.D., founder and CEO of Flagship Pioneering and founding Chairman of Cellarity.

  8. Show article details.

    Flagship Pioneering Unveils Latest Company: Invaio Sciences

    PR Newswire – 9:00 AM ET 05/27/2020

    CAMBRIDGE, Mass. Invaio Sciences has pioneered a novel approach to managing insect populations in a more sustainable and targeted way by controlling the nutritional function organ called the obligate microbial symbiont to alter insect health.

  9. Show article details.

    Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option

    Business Wire – 4:05 PM ET 05/18/2020

    Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, today announced the closing of its underwritten public offering of an aggregate of 12,650,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase additional shares, at a pub...

  10. Show article details.

    BRIEF-Axcella Announces Pricing Of Public Offering Of Common Stock

    Reuters – 10:36 PM ET 05/13/2020

    Axcella Health Inc (AXLA): * AXCELLA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK. * SAYS PUBLIC OFFERING OF 11.0 MILLION COMMON SHARES PRICED AT $4.75PER SHARE Source text for Eikon: Further company coverage:

  11. Show article details.

    Axcella Announces Pricing of Public Offering of Common Stock

    Business Wire – 10:31 PM ET 05/13/2020

    Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, today announced the pricing of its underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $4.75 per share, before deducting underwriting discounts and commissions.

  12. Show article details.

    BRIEF-Axcella Health Inc Files For Offering Of Up To 11.0 Mln Shares Of Common Stock

    Reuters – 7:03 PM ET 05/11/2020

    Axcella Health Inc (AXLA): * AXCELLA HEALTH INC FILES FOR OFFERING OF UP TO 11.0 MILLION SHARES OF COMMON STOCK - SEC FILING Source: Further company coverage:

  13. Show article details.

    BRIEF-Axcella Reports Q1 Loss Per Share Of $0.65

    Reuters – 8:17 AM ET 05/11/2020

    Axcella Health Inc (AXLA): * AXCELLA REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Q1 LOSS PER SHARE $0.65. * Q1 EARNINGS PER SHARE ESTIMATE $-0.86 -- REFINITIV IBES DATA. * AXCELLA HEALTH (AXLA) - REPORTED POSITIVE TOP-LINE DATA FROM AXA1125-003. * COMPLETED ENROLLMENT OF AXA1665-002, WITH DATA READOUT EXPECTED IN Q3 2020.

  14. Show article details.

    Axcella Reports First Quarter Financial Results and Provides Business Update

    Business Wire – 8:00 AM ET 05/11/2020

    CAMBRIDGE, Mass. “These past few months have been a particularly exciting period for Axcella, culminating in our recent report of positive top-line data for AXA1125, our NASH product candidate, that we believe further validates our platform,” said Bill Hinshaw, President and Chief Executive Officer of Axcella.

  15. Show article details.

    BRIEF-Axcella Announces Positive Top-Line Data From AXA1125-003 Clinical Study Showing Multifactorial Activity In Adult Subjects With NAFLD

    Reuters – 8:09 AM ET 05/06/2020

    Axcella Health Inc (AXLA): * AXCELLA ANNOUNCES POSITIVE TOP-LINE DATA FROM AXA1125-003 CLINICAL STUDY SHOWING MULTIFACTORIAL ACTIVITY IN ADULT SUBJECTS WITH NAFLD. * Axcella Health Inc (AXLA) - GREATER ACTIVITY IN KEY MARKERS SEEN AMONG SUBJECTS WITH TYPE 2 DIABETES RECEIVING AXA1125.

  16. Show article details.

    Axcella Announces Positive Top-Line Data from AXA1125-003 Clinical Study Showing Multifactorial Activity in Adult Subjects with NAFLD

    Business Wire – 8:00 AM ET 05/06/2020

    CAMBRIDGE, Mass. AXA1125-003 is a placebo-controlled, randomized, multi-arm clinical study assessing the impact of AXA1125 and AXA1957 on safety, tolerability and effects on structures and functions of the liver, as measured by a comprehensive panel of imaging and soluble biomarkers related to metabolism, inflammation and fibrosis.

  17. Show article details.

    Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD on May 6, 2020

    Business Wire – 4:05 PM ET 05/05/2020

    Company to hold conference call at 8:30 a.m. ET Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, today announced that it plans to report top-line data from AXA1125-003 on May 6, 2020 and will host a conference call at 8:30 a.m. ET that morning.

  18. Show article details.

    Axcella to Hold Virtual-Only 2020 Annual Meeting of Stockholders

    Business Wire – 4:05 PM ET 05/04/2020

    Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, today announced that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format due to the continued public health impact of the coronavirus outbreak and to support the health and well-being of its ...

Page:

Today's and Upcoming Events

  • Aug
    14

    AXLA to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    11

    AXLA announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.